Recursion Pharmaceuticals (RXRX) Stock Chart & Stock Price History $6.04 -0.23 (-3.67%) (As of 11/20/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Recursion Pharmaceuticals Stock Price Performance 5 Day Performance-2.19%1 Month Performance-12.97%3 Month Performance-15.64%6 Month Performance-38.24%Year-To-Date Performance-38.74%1 Year Performance-11.95% Receive RXRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. RXRX Stock Chart for Thursday, November, 21, 2024 RXRX Chart by TradingView Recursion Pharmaceuticals Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/20/2024$6.27$6.04-3.67%$6.37$5.7016.99 million shs$1.73 billion11/19/2024$6.10$6.27+2.79%$6.33$5.849.32 million shs$1.80 billion11/18/2024$6.18$6.10-1.21%$6.26$5.9010.40 million shs$1.71 billion11/15/2024$6.91$6.18-10.64%$6.92$6.1510.53 million shs$1.74 billion11/14/2024$7.32$6.91-5.60%$7.58$6.886.57 million shs$1.94 billion11/13/2024$7.58$7.32-3.43%$8.04$7.316.58 million shs$2.06 billion Get the Latest News and Ratings for RXRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/12/2024$7.84$7.58-3.32%$8.05$7.436.79 million shs$2.13 billion11/11/2024$7.10$7.84+10.42%$8.49$7.2315.53 million shs$2.20 billion11/08/2024$6.93$7.10+2.45%$7.20$6.816.66 million shs$2.00 billion11/07/2024$6.97$6.93-0.57%$7.09$6.685.79 million shs$1.95 billion11/06/2024$6.82$6.97+2.20%$7.05$6.787.28 million shs$1.96 billion11/05/2024$6.64$6.82+2.71%$6.83$6.474.33 million shs$1.92 billion11/04/2024$6.40$6.64+3.75%$6.69$6.223.88 million shs$1.87 billion11/01/2024$6.32$6.40+1.27%$6.58$6.343.63 million shs$1.80 billion10/31/2024$6.68$6.32-5.39%$6.69$6.324.38 million shs$1.78 billion10/30/2024$6.74$6.68-0.89%$6.90$6.604.47 million shs$1.88 billion10/29/2024$6.87$6.74-1.89%$6.84$6.662.49 million shs$1.89 billion10/28/2024$6.48$6.87+6.02%$6.95$6.564.54 million shs$1.93 billion10/25/2024$6.36$6.48+1.89%$6.61$6.283.51 million shs$1.82 billion10/24/2024$6.33$6.36+0.47%$6.45$6.202.90 million shs$1.79 billion10/23/2024$6.61$6.33-4.24%$6.63$6.243.96 million shs$1.50 billion10/22/2024$6.76$6.61-2.22%$6.79$6.562.83 million shs$1.57 billion10/21/2024$6.94$6.76-2.59%$6.94$6.593.93 million shs$1.61 billion Related Companies Schrödinger Stock Chart Arcus Biosciences Stock Chart Relay Therapeutics Stock Chart AbCellera Biologics Stock Chart Exscientia Stock Chart Emergent BioSolutions Stock Chart Absci Stock Chart Legend Biotech Stock Chart Elanco Animal Health Stock Chart Blueprint Medicines Stock Chart Receive RXRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
